Henan Taloph Pharmaceutical Stock Co Ltd Asset Resilience Ratio
Henan Taloph Pharmaceutical Stock Co Ltd asset resilience ratio. Henan Taloph Pharmaceutical Stock Co Ltd (600222) has an Asset Resilience Ratio of 2.75% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Henan Taloph Pharmaceutical Stock Co Ltd (600222) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Henan Taloph Pharmaceutical Stock Co Ltd (2014–2025)
Asset resilience ratio of Henan Taloph Pharmaceutical Stock Co Ltd from 2014 to 2025. This chart shows how Henan Taloph Pharmaceutical Stock Co Ltd's Asset Resilience Ratio has changed over time. Read how much debt does Henan Taloph Pharmaceutical Stock Co Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Henan Taloph Pharmaceutical Stock Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Henan Taloph Pharmaceutical Stock Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥100.02 Million | 2.75% |
| Total Liquid Assets | CN¥100.02 Million | 2.75% |
Asset Resilience Insights
- Limited Liquidity: Henan Taloph Pharmaceutical Stock Co Ltd maintains only 2.75% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Henan Taloph Pharmaceutical Stock Co Ltd Industry Peers by Asset Resilience Ratio
Compare Henan Taloph Pharmaceutical Stock Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Henan Taloph Pharmaceutical Stock Co Ltd Asset Resilience Ratio by Year (2014–2025)
Henan Taloph Pharmaceutical Stock Co Ltd asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Henan Taloph Pharmaceutical Stock Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.75% | CN¥100.02 Million ≈ $14.64 Million |
CN¥3.64 Billion ≈ $532.87 Million |
+0.45pp |
| 2024-12-31 | 2.29% | CN¥80.02 Million ≈ $11.71 Million |
CN¥3.49 Billion ≈ $510.66 Million |
-1.99pp |
| 2023-12-31 | 4.29% | CN¥153.30 Million ≈ $22.43 Million |
CN¥3.58 Billion ≈ $523.41 Million |
+2.20pp |
| 2022-12-31 | 2.08% | CN¥74.96 Million ≈ $10.97 Million |
CN¥3.60 Billion ≈ $526.82 Million |
-5.47pp |
| 2021-12-31 | 7.55% | CN¥285.67 Million ≈ $41.80 Million |
CN¥3.78 Billion ≈ $553.68 Million |
+1.43pp |
| 2020-12-31 | 6.12% | CN¥207.46 Million ≈ $30.36 Million |
CN¥3.39 Billion ≈ $495.98 Million |
-0.32pp |
| 2019-12-31 | 6.44% | CN¥176.40 Million ≈ $25.81 Million |
CN¥2.74 Billion ≈ $400.86 Million |
+1.87pp |
| 2018-12-31 | 4.57% | CN¥129.50 Million ≈ $18.95 Million |
CN¥2.84 Billion ≈ $414.90 Million |
+1.01pp |
| 2017-12-31 | 3.56% | CN¥100.00 Million ≈ $14.63 Million |
CN¥2.81 Billion ≈ $410.92 Million |
+1.29pp |
| 2015-12-31 | 2.27% | CN¥60.00 Million ≈ $8.78 Million |
CN¥2.64 Billion ≈ $386.25 Million |
-0.39pp |
| 2014-12-31 | 2.66% | CN¥61.00 Million ≈ $8.93 Million |
CN¥2.29 Billion ≈ $335.35 Million |
-- |
About Henan Taloph Pharmaceutical Stock Co Ltd
Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the research, development, and sale of pharmaceutical preparations and Chinese herbal medicines in China. Its principal products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, pediatric Qingrezhike oral liquid, Huoxiangzhengqi mixture, Danshen and Wuzi Yanzong oral liquid, Shengmaiyin, pediatric compound chicken gizzard chew… Read more